Mankind Pharma Q4 FY26: Margin rebound, deleveraging and a sharper pivot to specialty

Mankind Pharma closed FY26 with a Q4 that looked cleaner than the earlier quarters. Revenue from operations in Q4 FY26 rose to INR 3,443 crore, up 11.8% year on year. Profitability improved sharply, with reported EBITDA at INR 910 crore and an EBITDA margin of 26.4%. On an adjusted basis, EBITDA margin was 27.1% for the quarter, helped by a better mix and operating leverage.

For the full year, revenue increased 17.0% to INR 14,278 crore. Domestic business remained the anchor and grew 14.4% to INR 12,217 crore. Exports grew 34.5% to INR 2,061 crore, although Q4 export growth was muted at 4% due to geopolitical headwinds as described by management.

The year also reflected the after-effects of the BSV acquisition on the P&L. FY26 PAT was INR 1,938 crore, down 3.4% year on year. Management attributed the decline largely to higher finance costs and higher depreciation and amortization, alongside lower other income compared with FY25.

Q4 FY26 performance: domestic strength and a step-up in margins

Domestic business revenue in Q4 FY26 grew 13.4% year on year to INR 2,886 crore. Within this, domestic business excluding consumer healthcare was INR 2,673 crore, up 12.9% year on year. Consumer Healthcare revenue grew 19.8% to INR 213 crore.

The quarter’s margin expansion was notable. Gross margin rose 60 bps year on year to 72.2%. Management linked this to a better sales mix, citing higher chronic contribution. Adjusted EBITDA margin expanded to 27.1% in Q4 FY26 from 23.1% in Q4 FY25. The CFO described the drivers as gross margin improvement, operating leverage, and a relatively higher base of costs in the prior year due to launch and relaunch activity.

Financial summary

FY26 business mix: chronic share rising, OTC channels scaling

A key strategic theme was the company’s steady move toward higher chronic contribution. The presentation indicated Mankind’s chronic share increased by 190 bps in FY26 to about 38.5% (excluding BSV), with Q4 chronic share nearing 40%. Management highlighted outperformance metrics for cardiac and anti-diabetes on an annual basis, while acknowledging that quarterly growth multiples can move around.

The company continued to scale large brands. As per the deck, there were three brand families above INR 500 crore in FY26, and 13 brand families above INR 200 crore. Key brands above INR 500 crore included Telmikind (INR 783 crore), Nurokind (INR 667 crore) and Manforce (INR 647 crore).

Consumer Healthcare remained a smaller but strategic growth lever. FY26 revenue was INR 879 crore and Q4 revenue was INR 213 crore. The company called out the increasing importance of modern trade and e-commerce, with this channel mix reaching 13% in FY26 versus 9% in FY25, supported by 57% growth.

Exports and BSV: strong full-year growth, but near-term volatility

Exports delivered strong growth for the year, rising to INR 2,061 crore in FY26 from INR 1,532 crore in FY25. However, Q4 export growth slowed to 4% year on year. Management pointed to geopolitical headwinds and also referenced softness in some geographies for BSV’s international operations such as LATAM, CIS/RCIS and the Philippines.

On the BSV portfolio, management reiterated the strategic rationale of adding a high entry barrier super specialty portfolio. They also highlighted momentum in women’s health and fertility brands, citing strong growth in Foligraf and HMG during the quarter, and described AntiD as having full market share in India.

Cash flows, capex and leverage: deleveraging continues

The financial update indicated a stronger cash conversion profile in FY26. Cash flow from operations was INR 3,121 crore in FY26, and CFO to EBITDA ratio improved to 89%.

Capex increased to INR 737 crore in FY26, equivalent to 5.2% of revenue. Management guided that FY27 capex could increase to 6% to 7% of revenue, linked to the planned Vadodara biotech facility, with a board-approved investment of up to INR 500 crore in subsidiary Mankind Medicare for this purpose.

Net debt declined to INR 3,932 crore as of March 31, 2026 and net debt to adjusted EBITDA was 1.1x. Management reiterated that it remains on track to repay acquisition-related debt by FY28 and also stated a net debt to adjusted EBITDA guidance of 0.5x for FY27.

FY27 outlook: margin guidance, tax step-up and focus areas

Management provided a clearer forward view on profitability than on revenue. For FY27, the EBITDA margin guidance was 25.5% to 26.5%, with caveats around geopolitical and market conditions. On growth, management stated it expects a better year than FY26 with double-digit top line growth and an aspiration to outperform the market.

A major FY27 headwind is the tax reset. The CFO stated the effective tax rate in FY27 is expected to rise to 25% to 26%, because FY26 was the last year of the Sikkim tax exemption benefit.

Overall, the quarter reinforced three themes: improved execution in the base domestic business, a deliberate shift toward chronic and specialty, and steady deleveraging after BSV. The FY27 margin guidance and the capex plan for Vadodara suggest management is trying to balance near-term delivery with longer-term capability building.